Global Blood Cancer Drugs Market Research Report 2026

List of Tables

The global Blood Cancer Drugs market was valued at US$ 74605 million in 2025 and is anticipated to reach US$ 138811 million by 2032, at a CAGR of 9.21% from 2026 to 2032.

The North American market for Blood Cancer Drugs is projected to increase from US$ 36621 million in 2025 to US$ 62671 million by 2032, at a CAGR of 7.79% over 2026-2032.

The Asia-Pacific market for Blood Cancer Drugs is projected to rise from US$ 18666 million in 2025 to US$ 41952 million by 2032, at a CAGR of 12.35% over 2026-2032.

Major global companies of Blood Cancer Drugs include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, etc. In 2025, the world's top three vendors accounted for approximately 49.54% of revenue.

This report delivers a comprehensive overview of the global Blood Cancer Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Blood Cancer Drugs. The Blood Cancer Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021-2032.

The report segments the global Blood Cancer Drugs market comprehensively. Regional market sizes by Type, by Disease, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Blood Cancer Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Disease, and by region.

Market Segmentation

By Company

Johnson & Johnson
Bristol-Myers Squibb
Novartis
AbbVie
Roche
BeiGene
Amgen
AstraZeneca
Incyte Corporation
Takeda
Gilead Sciences
Pfizer
Sanofi
Astellas Pharma

Segment by Type

Chemotherapy
Targeted Therapy
Immunotherapy
Other

Segment by Disease

Leukemia
Lymphoma
Multiple Myeloma

Segment by Region

North America
- U.S.
- Canada
- Mexico
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe
South America
- Brazil
Middle East & Africa
- Middle East
- Africa

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Disease, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Blood Cancer Drugs companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Disease, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 6-10: Regional deep dives (North America, Europe, Asia Pacific, South America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

1 Report Overview

1.1 Study Scope
1.2 Market Analysis by Type
- 1.2.1 Global Blood Cancer Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
- 1.2.2 Chemotherapy
- 1.2.3 Targeted Therapy
- 1.2.4 Immunotherapy
1.3 Market by Disease
- 1.3.1 Global Blood Cancer Drugs Market Growth by Disease: 2021 vs 2025 vs 2032
- 1.3.2 Leukemia
- 1.3.3 Lymphoma
- 1.3.4 Multiple Myeloma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends

2.1 Global Blood Cancer Drugs Market Perspective (2021-2032)
2.2 Global Blood Cancer Drugs Growth Trends by Region
- 2.2.1 Global Blood Cancer Drugs Market Size by Region: 2021 vs 2025 vs 2032
- 2.2.2 Blood Cancer Drugs Historic Market Size by Region (2021-2026)
- 2.2.3 Blood Cancer Drugs Forecasted Market Size by Region (2027-2032)
2.3 Blood Cancer Drugs Market Dynamics
- 2.3.1 Blood Cancer Drugs Industry Trends
- 2.3.2 Blood Cancer Drugs Market Drivers
- 2.3.3 Blood Cancer Drugs Market Challenges
- 2.3.4 Blood Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Blood Cancer Drugs Players by Revenue
- 3.1.1 Global Top Blood Cancer Drugs Players by Revenue (2021-2026)
- 3.1.2 Global Blood Cancer Drugs Revenue Market Share by Players (2021-2026)
3.2 Global Top Blood Cancer Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Blood Cancer Drugs Revenue
3.4 Global Blood Cancer Drugs Market Concentration Ratio
- 3.4.1 Global Blood Cancer Drugs Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Blood Cancer Drugs Revenue in 2025
3.5 Global Key Players of Blood Cancer Drugs Head Offices and Areas Served
3.6 Global Key Players of Blood Cancer Drugs, Products
3.7 Global Key Players of Blood Cancer Drugs, Founded Date
3.8 Mergers and Acquisitions, Expansion Plans

4 Blood Cancer Drugs Breakdown Data by Type

4.1 Global Blood Cancer Drugs Historic Market Size by Type (2021-2026)
4.2 Global Blood Cancer Drugs Forecasted Market Size by Type (2027-2032)

5 Blood Cancer Drugs Breakdown Data by Disease

5.1 Global Blood Cancer Drugs Historic Market Size by Disease (2021-2026)
5.2 Global Blood Cancer Drugs Forecasted Market Size by Disease (2027-2032)

6 North America

6.1 North America Blood Cancer Drugs Market Size (2021-2032)
6.2 North America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Blood Cancer Drugs Market Size by Country (2021-2026)
6.4 North America Blood Cancer Drugs Market Size by Country (2027-2032)
6.5 United States
6.6 Canada
6.7 Mexico

7 Europe

7.1 Europe Blood Cancer Drugs Market Size (2021-2032)
7.2 Europe Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Blood Cancer Drugs Market Size by Country (2021-2026)
7.4 Europe Blood Cancer Drugs Market Size by Country (2027-2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia

8 Asia-Pacific

8.1 Asia-Pacific Blood Cancer Drugs Market Size (2021-2032)
8.2 Asia-Pacific Blood Cancer Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region (2021-2026)
8.4 Asia-Pacific Blood Cancer Drugs Market Size by Region (2027-2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India

9 South America

9.1 South America Blood Cancer Drugs Market Size (2021-2032)
9.2 South America Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 South America Blood Cancer Drugs Market Size by Country (2021-2026)
9.4 South America Blood Cancer Drugs Market Size by Country (2027-2032)
9.5 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Blood Cancer Drugs Market Size (2021-2032)
10.2 Middle East & Africa Blood Cancer Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country (2021-2026)
10.4 Middle East & Africa Blood Cancer Drugs Market Size by Country (2027-2032)
10.5 Middle East
10.6 Africa

11 Key Players Profiles

11.1 Bristol-Myers Squibb
- 11.1.1 Bristol-Myers Squibb Company Details
- 11.1.2 Bristol-Myers Squibb Business Overview
- 11.1.3 Bristol-Myers Squibb Blood Cancer Drugs Introduction
- 11.1.4 Bristol-Myers Squibb Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.1.5 Bristol-Myers Squibb Recent Development
11.2 Johnson & Johnson
- 11.2.1 Johnson & Johnson Company Details
- 11.2.2 Johnson & Johnson Business Overview
- 11.2.3 Johnson & Johnson Blood Cancer Drugs Introduction
- 11.2.4 Johnson & Johnson Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.2.5 Johnson & Johnson Recent Development
11.3 AbbVie
- 11.3.1 AbbVie Company Details
- 11.3.2 AbbVie Business Overview
- 11.3.3 AbbVie Blood Cancer Drugs Introduction
- 11.3.4 AbbVie Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.3.5 AbbVie Recent Development
11.4 Novartis
- 11.4.1 Novartis Company Details
- 11.4.2 Novartis Business Overview
- 11.4.3 Novartis Blood Cancer Drugs Introduction
- 11.4.4 Novartis Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.4.5 Novartis Recent Development
11.5 Roche
- 11.5.1 Roche Company Details
- 11.5.2 Roche Business Overview
- 11.5.3 Roche Blood Cancer Drugs Introduction
- 11.5.4 Roche Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.5.5 Roche Recent Development
11.6 Amgen
- 11.6.1 Amgen Company Details
- 11.6.2 Amgen Business Overview
- 11.6.3 Amgen Blood Cancer Drugs Introduction
- 11.6.4 Amgen Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.6.5 Amgen Recent Development
11.7 Takeda
- 11.7.1 Takeda Company Details
- 11.7.2 Takeda Business Overview
- 11.7.3 Takeda Blood Cancer Drugs Introduction
- 11.7.4 Takeda Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.7.5 Takeda Recent Development
11.8 Pfizer
- 11.8.1 Pfizer Company Details
- 11.8.2 Pfizer Business Overview
- 11.8.3 Pfizer Blood Cancer Drugs Introduction
- 11.8.4 Pfizer Revenue in Blood Cancer Drugs Business (2021-2026)
11.9 AstraZeneca
- 11.9.1 AstraZeneca Company Details
- 11.9.2 AstraZeneca Business Overview
- 11.9.3 AstraZeneca Blood Cancer Drugs Introduction
- 11.9.4 AstraZeneca Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.9.5 AstraZeneca Recent Development
11.10 Gilead Sciences
- 11.10.1 Gilead Sciences Company Details
- 11.10.2 Gilead Sciences Business Overview
- 11.10.3 Gilead Sciences Blood Cancer Drugs Introduction
- 11.10.4 Gilead Sciences Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.10.5 Gilead Sciences Recent Development
11.11 Sanofi
- 11.11.1 Sanofi Company Details
- 11.11.2 Sanofi Business Overview
- 11.11.3 Sanofi Blood Cancer Drugs Introduction
- 11.11.4 Sanofi Revenue in Blood Cancer Drugs Business (2021-2026)
11.12 Incyte Corporation
- 11.12.1 Incyte Corporation Company Details
- 11.12.2 Incyte Corporation Business Overview
- 11.12.3 Incyte Corporation Blood Cancer Drugs Introduction
- 11.12.4 Incyte Corporation Revenue in Blood Cancer Drugs Business (2021-2026)
11.13 BeiGene
- 11.13.1 BeiGene Company Details
- 11.13.2 BeiGene Business Overview
- 11.13.3 BeiGene Blood Cancer Drugs Introduction
- 11.13.4 BeiGene Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.13.5 BeiGene Recent Development
11.14 Astellas Pharma
- 11.14.1 Astellas Pharma Company Details
- 11.14.2 Astellas Pharma Business Overview
- 11.14.3 Astellas Pharma Blood Cancer Drugs Introduction
- 11.14.4 Astellas Pharma Revenue in Blood Cancer Drugs Business (2021-2026)
- 11.14.5 Astellas Pharma Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

Table 1. Global Blood Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Blood Cancer Drugs Market Size Growth by Disease (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Blood Cancer Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 4. Global Blood Cancer Drugs Market Size by Region (US$ Million), 2021-2026
Table 5. Global Blood Cancer Drugs Market Share by Region (2021-2026)
Table 6. Global Blood Cancer Drugs Forecasted Market Size by Region (US$ Million), 2027-2032
Table 7. Global Blood Cancer Drugs Market Share by Region (2027-2032)
Table 8. Blood Cancer Drugs Market Trends
Table 9. Blood Cancer Drugs Market Drivers
Table 10. Blood Cancer Drugs Market Challenges
Table 11. Blood Cancer Drugs Market Restraints
Table 12. Global Blood Cancer Drugs Revenue by Players (US$ Million), 2021-2026
Table 13. Global Blood Cancer Drugs Market Share by Players (2021-2026)
Table 14. Global Top Blood Cancer Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Blood Cancer Drugs Revenue, 2025
Table 15. Ranking of Global Top Blood Cancer Drugs Companies by Revenue (US$ Million) in 2025
Table 16. Global 5 Largest Players Market Share by Blood Cancer Drugs Revenue (CR5 and HHI), 2021-2026
Table 17. Global Key Players of Blood Cancer Drugs, Headquarters and Area Served
Table 18. Global Key Players of Blood Cancer Drugs, Products
Table 19. Global Key Players of Blood Cancer Drugs, Founded Date
Table 20. Mergers and Acquisitions, Expansion Plans
Table 21. Global Blood Cancer Drugs Market Size by Type (US$ Million), 2021-2026
Table 22. Global Blood Cancer Drugs Revenue Market Share by Type (2021-2026)
Table 23. Global Blood Cancer Drugs Forecasted Market Size by Type (US$ Million), 2027-2032
Table 24. Global Blood Cancer Drugs Revenue Market Share by Type (2027-2032)
Table 25. Global Blood Cancer Drugs Market Size by Disease (US$ Million), 2021-2026
Table 26. Global Blood Cancer Drugs Revenue Market Share by Disease (2021-2026)
Table 27. Global Blood Cancer Drugs Forecasted Market Size by Disease (US$ Million), 2027-2032
Table 28. Global Blood Cancer Drugs Revenue Market Share by Disease (2027-2032)
Table 29. North America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 30. North America Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
Table 31. North America Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
Table 32. Europe Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 33. Europe Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
Table 34. Europe Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
Table 35. Asia-Pacific Blood Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 36. Asia-Pacific Blood Cancer Drugs Market Size by Region (US$ Million), 2021-2026
Table 37. Asia-Pacific Blood Cancer Drugs Market Size by Region (US$ Million), 2027-2032
Table 38. South America Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 39. South America Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
Table 40. South America Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
Table 41. Middle East & Africa Blood Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. Middle East & Africa Blood Cancer Drugs Market Size by Country (US$ Million), 2021-2026
Table 43. Middle East & Africa Blood Cancer Drugs Market Size by Country (US$ Million), 2027-2032
Table 44. Bristol-Myers Squibb Company Details
Table 45. Bristol-Myers Squibb Business Overview
Table 46. Bristol-Myers Squibb Blood Cancer Drugs Product
Table 47. Bristol-Myers Squibb Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 48. Bristol-Myers Squibb Recent Development
Table 49. Johnson & Johnson Company Details
Table 50. Johnson & Johnson Business Overview
Table 51. Johnson & Johnson Blood Cancer Drugs Product
Table 52. Johnson & Johnson Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 53. Johnson & Johnson Recent Development
Table 54. AbbVie Company Details
Table 55. AbbVie Business Overview
Table 56. AbbVie Blood Cancer Drugs Product
Table 57. AbbVie Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 58. AbbVie Recent Development
Table 59. Novartis Company Details
Table 60. Novartis Business Overview
Table 61. Novartis Blood Cancer Drugs Product
Table 62. Novartis Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 63. Novartis Recent Development
Table 64. Roche Company Details
Table 65. Roche Business Overview
Table 66. Roche Blood Cancer Drugs Product
Table 67. Roche Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 68. Roche Recent Development
Table 69. Amgen Company Details
Table 70. Amgen Business Overview
Table 71. Amgen Blood Cancer Drugs Product
Table 72. Amgen Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 73. Amgen Recent Development
Table 74. Takeda Company Details
Table 75. Takeda Business Overview
Table 76. Takeda Blood Cancer Drugs Product
Table 77. Takeda Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 78. Takeda Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Blood Cancer Drugs Product
Table 82. Pfizer Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 83. AstraZeneca Company Details
Table 84. AstraZeneca Business Overview
Table 85. AstraZeneca Blood Cancer Drugs Product
Table 86. AstraZeneca Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 87. AstraZeneca Recent Development
Table 88. Gilead Sciences Company Details
Table 89. Gilead Sciences Business Overview
Table 90. Gilead Sciences Blood Cancer Drugs Product
Table 91. Gilead Sciences Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 92. Gilead Sciences Recent Development
Table 93. Sanofi Company Details
Table 94. Sanofi Business Overview
Table 95. Sanofi Blood Cancer Drugs Product
Table 96. Sanofi Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 97. Incyte Corporation Company Details
Table 98. Incyte Corporation Business Overview
Table 99. Incyte Corporation Blood Cancer Drugs Product
Table 100. Incyte Corporation Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 101. BeiGene Company Details
Table 102. BeiGene Business Overview
Table 103. BeiGene Blood Cancer Drugs Product
Table 104. BeiGene Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 105. BeiGene Recent Development
Table 106. Astellas Pharma Company Details
Table 107. Astellas Pharma Business Overview
Table 108. Astellas Pharma Blood Cancer Drugs Product
Table 109. Astellas Pharma Revenue in Blood Cancer Drugs Business (US$ Million), 2021-2026
Table 110. Astellas Pharma Recent Development
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
Table 114. Authors List of This Report

List of Figures

Figure 1. Blood Cancer Drugs Picture
Figure 2. Global Blood Cancer Drugs Market Size Comparison by Type (US$ Million), 2021-2032
Figure 3. Global Blood Cancer Drugs Market Share by Type: 2025
Figure 4. Global Blood Cancer Drugs Market Share by Type: 2032
Figure 5. Chemotherapy Features
Figure 6. Targeted Therapy Features
Figure 7. Immunotherapy Features
Figure 8. Global Blood Cancer Drugs Market Size by Disease (US$ Million), 2021-2032
Figure 9. Global Blood Cancer Drugs Market Share by Disease: 2025
Figure 10. Global Blood Cancer Drugs Market Share by Disease: 2032
Figure 11. Leukemia Case Studies
Figure 12. Lymphoma Case Studies
Figure 13. Multiple Myeloma Case Studies
Figure 14. Blood Cancer Drugs Report Years Considered
Figure 15. Global Blood Cancer Drugs Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 16. Global Blood Cancer Drugs Market Size, (US$ Million), 2021 vs 2026 vs 2032
Figure 17. Global Blood Cancer Drugs Market Share by Region: 2025
Figure 18. Global Blood Cancer Drugs Market Share by Region: 2032
Figure 19. Global Blood Cancer Drugs Market Share by Players in 2025
Figure 20. The Top 5 Players Market Share by Blood Cancer Drugs Revenue in 2025
Figure 21. The Top 10 Players Market Share by Blood Cancer Drugs Revenue in 2025
Figure 22. North America Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 23. North America Blood Cancer Drugs Market Share by Country (2021-2032)
Figure 24. United States Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 25. Canada Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 26. Mexico Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 27. Europe Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 28. Europe Blood Cancer Drugs Market Share by Country (2021-2032)
Figure 29. Germany Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 30. France Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 31. U.K. Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 32. Italy Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 33. Russia Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 34. Asia-Pacific Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 35. Asia-Pacific Blood Cancer Drugs Market Share by Region (2021-2032)
Figure 36. China Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 37. Japan Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 38. South Korea Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 39. Southeast Asia Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 40. India Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 41. South America Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 42. South America Blood Cancer Drugs Market Share by Country (2021-2032)
Figure 43. Brazil Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 44. Middle East & Africa Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 45. Middle East & Africa Blood Cancer Drugs Market Share by Country (2021-2032)
Figure 46. Middle East Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 47. Africa Blood Cancer Drugs Market Size YoY Growth (US$ Million), 2021-2032
Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 49. Johnson & Johnson Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 50. AbbVie Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 51. Novartis Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 52. Roche Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 53. Amgen Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 54. Takeda Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 55. Pfizer Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 56. AstraZeneca Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 57. Gilead Sciences Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 58. Sanofi Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 59. Incyte Corporation Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 60. BeiGene Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 61. Astellas Pharma Revenue Growth Rate in Blood Cancer Drugs Business (2021-2026)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed